A5081015329- Cancer Immunotherapy and Biomarkers
- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- Esophageal Cancer Research and Treatment
- Cancer Genomics and Diagnostics
- Immunotherapy and Immune Responses
- Genetic factors in colorectal cancer
- Palliative Care and End-of-Life Issues
- Neuroendocrine Tumor Research Advances
- Cancer survivorship and care
- Colorectal and Anal Carcinomas
- Peptidase Inhibition and Analysis
- Family Support in Illness
- Ocular Oncology and Treatments
- Melanoma and MAPK Pathways
- Ferroptosis and cancer prognosis
- Chronic Lymphocytic Leukemia Research
- Cancer therapeutics and mechanisms
- Neutropenia and Cancer Infections
- Chronic Myeloid Leukemia Treatments
- Gastric Cancer Management and Outcomes
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Cutaneous lymphoproliferative disorders research
- Multiple and Secondary Primary Cancers
University of Calgary
2019-2025
Sidney Kimmel Comprehensive Cancer Center
2024
Johns Hopkins University
2024
Sidney Kimmel Cancer Center
2024
Johns Hopkins Medicine
2024
Harvard University
2023
Alberta Health Services
2021-2023
Abbott (United Kingdom)
2022
Weatherford College
2022
University of Alberta
2014-2022
The aim of the current study was to report efficacy topical and systemic treatments for immune-related cutaneous adverse events (ircAEs) attributed checkpoint inhibitors in an uncontrolled cohort patients referred oncodermatology clinics.
Importance Immune-related adverse events (irAEs) secondary to immune checkpoint inhibitor (ICI) therapy reportedly improve overall survival (OS) in patients with non–small cell lung cancer (NSCLC). However, studies have been small and the association between irAE severity OS remains poorly defined. Objective To examine irAEs their locally advanced or metastatic NSCLC receiving ICIs. Design, Setting, Participants This retrospective observational cohort study included ICIs March 1, 2014,...
Background Artificial intelligence (AI) chatbots have become a major source of general and medical information, though their accuracy completeness are still being assessed. Their utility to answer questions surrounding immune-related adverse events (irAEs), common potentially dangerous toxicities from cancer immunotherapy, not well defined. Methods We developed 50 distinct with answers in available guidelines 10 irAE categories queried two AI (ChatGPT Bard), along an additional 20...
Immune checkpoint inhibitors (ICI) have revolutionized the treatment landscape of several solid tumor types. However, as patient outcomes are heterogeneous, clinical tools to aid in prognostication needed. The Lung Prognostic Index (LIPI) correlates with patients non-small cell lung cancer (NSCLC) treated ICI, but its applicability beyond NSCLC is poorly defined. We sought determine whether LIPI associated overall survival (OS), progression-free (PFS) and objective response rate (ORR) a...
Immune-related adverse events (irAEs) due to immune checkpoint blockade (ICB) have been shown be positively associated with survival. Among patients metastatic melanoma, evidence supporting this association has conflicting, while ipilimumab-nivolumab combination ICB examined only in small clinical cohorts.To examine the between irAEs and survival among particular for those receiving ICB.A retrospective cohort of 492 consecutive melanoma treated at 2 tertiary 4 regional cancer centers...
BackgroundImmuno-oncology (IO)–based therapies have been approved based on randomised clinical trials, yet a significant proportion of real-world patients are not represented in these trials. We sought to compare the outcomes trial-ineligible vs. -eligible with advanced solid tumours treated first-line (1L) IO therapy.Patients and methodsUsing International Metastatic Renal Cell Carcinoma (RCC) Database Consortium Alberta Immunotherapy Database, RCC, non–small-cell lung cancer (NSCLC) or...
BRAF mutations (present in 2%-3% of NSCLC) are a known oncogenic driver and emerging therapeutic target. There is scarcity real-world data describing the clinical characteristics, treatment patterns, effectiveness targeted BRAF-inhibiting immune checkpoint inhibitor (ICI)-based systemic therapies, yet this required for appropriate decisions that optimize patient outcome.Demographic, clinical, treatment, outcome patients with mutation-positive NSCLC diagnosed between 2018 2022 were identified...
ContextTimely palliative care can alleviate distress after diagnosis of an incurable cancer. However, late referrals to continue, reflecting various provider and patient barriers.ObjectiveTo determine patient/caregiver-reported acceptability a phone call offering supportive (SPC) consultation without requiring oncologist referral.MethodsTwo SPC nurses screened out-patient clinic lists at tertiary cancer center weekly called all eligible patients offer consultation. Eligibility: >18 years,...
The real-world data evaluating treatment outcomes of atezolizumab plus carboplatin-etoposide chemotherapy (atezolizumab) for extensive-stage SCLC (ESCLC) are lacking. Our objective was to evaluate ESCLC treated with atezolizumab.A retrospective analysis provincial patients who started first-line (1L) systemic conducted. We primarily evaluated the progression-free survival (PFS) and overall (OS) in association compared platinum-etoposide (chemotherapy) while adjusting relevant demographic...
Antimicrobial resistance (AMR) is a growing global public health concern and becoming significant challenge in the management of patients with cancer. Due to immunosuppressive nature cancer treatment, infection common complication necessary high usage antibiotics increases risk AMR. Failure adequately prevent treat as result AMR can increase morbidity mortality disease. The objective this scoping review understand relationship between order develop effective antimicrobial stewardship patient...
BACKGROUNDImmune-related adverse events (irAEs) and their associated morbidity/mortality are a key concern for patients receiving immune checkpoint inhibitors (ICIs). Prospective evaluation of the drivers irAEs in diverse pan-tumor cohort is needed to identify at greatest risk develop rational treatment interception strategies.METHODSIn an observational study, we prospectively collected blood samples performed regular clinical evaluations ICI therapy as standard care solid tumors. We...
The emergence of immunotherapy revolutionized the treatment non-small-cell-lung cancer (NSCLC), with multiple landmark clinical trials establishing efficacy these agents. However, many patients who receive in practice would be considered trial ineligible. One such population that is often under-represented older adults. In current study, we evaluated and safety outcomes this population. Overall, adults (>70 years age) younger had comparable an equivalent objective response rate (ORR), time...
Real-world evidence surrounding EGFR positive NSCLC patients in Canada is limited. Administrative databases Alberta, were used to evaluate testing and mutation prevalence de novo metastatic NSCLC, as well the characteristics, treatment patterns, outcomes of individuals with Exon 19, L858R Exon20ins mutations. Between 2013–2019, 2974 underwent testing, which 451 (15.2%) positive. Among individuals, 221 (49.0%) had an 19 mutation, 159 (35.3%) 18 (4%) mutation. The proportion who initiated 1L...
Abstract Purpose Timely access to supportive and palliative care (PC) remains a challenge. A proposed solution is trigger an automatic referral process PC by pre-determined clinical criteria. This study sought co-design with patients providers for newly diagnosed stage IV lung cancer. Methods In Step 1 of this work, nine one on phone interviews were conducted advanced cancer their perspectives the acceptability contact specialist provider triggered process. Interviews thematically analysed....
The use, safety and effectiveness of crizotinib as part the management ROS1-rearranged NSCLC patients in a real-world Canadian clinical cohort was focus this retrospective review. Twenty-one with advanced/metastatic disease receiving between 2014–2020 were identified; demonstrated tolerability population where outcomes similar to those described other crizotinib-treated cohorts, but lower than PROFILE 1001 trial population. Systemic anti-cancer therapy prior initiation occurred half study...
The PACIFIC trial led to a new standard of care for patients with locally advanced lung cancer, but real-world practice has demonstrated that immune checkpoint inhibitor (ICI) pneumonitis can lead significant clinical complications. This study aimed examine the predictors, outcomes, and healthcare utilization data in who received consolidation durvalumab. Using Alberta Immunotherapy Database, NSCLC durvalumab Alberta, Canada, from January 2018 December 2021 were retrospectively evaluated. We...
Abstract Rationale: Small cell carcinoma (SCC) is a rare subtype of breast cancer and presents complex diagnostic treatment challenge, due to paucity data. To the best our knowledge, most cases SCC reported in literature describe de novo primary. Our case unique as it describes evolution an invasive ductal after into breast. Patient concerns diagnosis: We report 53-year-old female, lifelong non-smoker, who initially presented with mass noted on self examination. Breast axillary lymph node...